



February 12, 2014

FOR IMMEDIATE RELEASE:

Contact:

Daniel Lawson

Neuronetrix

1044 E. Chestnut St.

Louisville KY 40204

(502) 561-9040, x7003

dlawson@neuronetrix.com

www.neuronetrix.com

Neuronetrix Completes Significant Clinical Study Milestone Using the COGNISION™ System for Early Diagnosis of Alzheimer's Disease


Louisville, KY — Louisville, KY — Neuronetrix has completed a significant clinical study milestone involving their proprietary COGNISION™ System. The multi-year study was designed to evaluate the system's ability to discriminate early stage Alzheimer's patients from age-matched healthy controls.

The trial enrolled over 200 subjects at seven sites in the US. During the trial, the COGNISION™ System recorded cognitive brainwave activity from patients with mild Alzheimer's disease and from healthy subjects. The brainwave data was then compared to standard clinical criteria for the diagnosis of Alzheimer's disease. The study also included a testing protocol from the Alzheimer's Disease Neuroimaging Initiative (ADNI) that consisted of psychological tests, lab tests, DNA sequencing, and MRI. Correlations between these biomarkers and the COGNISION™ test data are being developed.

We are very pleased to have completed this complex clinical study and are grateful to the clinicians and technicians who were integral to our success," said Dr. Marco Cecchi, Neuronetrix's Director of Research and Clinical Affairs. "We look forward to publishing our results which should demonstrate the clinical utility of COGNISION™."

In November 2013, positive preliminary data from the study were presented at the Clinical Trials for Alzheimer's Disease (CTAD) conference in San Diego. The completed analysis and study conclusions will be submitted for peer reviewed publication in the coming months.

Additional information on the trial can be found at ClinicalTrials.Gov.



About COGNISION™

The COGNISION™ System is a proprietary neuro-electrophysiological device which provides objective assessments of cognitive function. COGNISION™ implements powerful and validated scientific methods in a practical, cost effective, and easy to use design.

About Neuronetrix

Neuronetrix, developer of the COGNISION™, is a leading neurotech company focused on providing physicians and scientists with accurate and meaningful information about brain processing. This information is critical in the understanding of complex brain function, diagnosis of cognitive disorders, and evaluating the effects of pro-cognitive therapies.

Information about Neuronetrix is available at <http://www.neuronetrix.com> or by contacting Daniel Lawson at dlawson@neuronetrix.com, or (502) 561-9040, x7003.

###